NextCure Corporation - NXTC Company Short-Term Debt

NextCure (NXTC) - corporate logo

NextCure, Inc. (NXTC) utilizes the FIND platform to identify proteins that block immunity in cancer. The company's US laboratories create unique targets within tumors, while current antibody clinical trials serve as long-term growth drivers. Debt maturing within one year confirms these data, and its current value is 0.00, demonstrating the issuer's liquidity management strategy.

NXTC: nextcure.com Short-Term Debt 07/04/2022 - 10/29/2026

NXTC (NextCure Corporation): analytical breakdowns and indicator data

- price and consensus price forecast:
Price Chart NextCure|NXTC - Average Forecast Price
- market capitalization data:
Market Value NextCure, Inc.|NXTC - Total Company Value
- book capitalization data:
Net Assets per Single Share NextCure|NXTC - Total Stockholders' Equity|Market Capitalization to Book Value Ratio nextcure.com|NXTC - Company Balance Sheet Assets
- debt and liquidity data:
Total Debt to Equity Ratio NextCure, Inc.|NXTC - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio NextCure, Inc.|NXTC - Aggregate Debt Obligations|Debts to Book Capitalization NextCure, Inc.|NXTC - Long-Term Debt Volume|Company Short-Term Debt NextCure
Analysis of all company metrics:NextCure NXTC
Finished products of nextcure.com

Monitoring the volatility of short-term liabilities, which measures daily fluctuations in debt totals to assess liquidity and listing compliance, is critical for building a resilient portfolio. In the case of NextCure, Inc. (NXTC), this metric reflects the balance between R&D expenditures and external financing; therefore, the current level of short-term liabilities serves as an indicator of the company's ability to sustain clinical trials without the risk of default.

Competitor analysis for NextCure, Inc.

IBRX (ImmunityBio) - Company Short-Term Debt|IMCR: Short-Term Debt|Janux Pharma (JANX) - Company Short-Term Debt|RCUS (Arcus Corp) - Company Short-Term Debt|Company Short-Term Debt ZYME (Zymeworks Inc.)|Short-Term Debt tangotx.com|IOVA: Company Short-Term Debts|Short-Term Indebtedness Immatics NV IMTX|XNCR: Company Current Liabilities|CMPX - Short-Term Debt|Company Current Liabilities Replimune Group, Inc. (REPL)|LYEL - Company Short-Term Loans and Borrowings|Innate Pharma - Company Short-Term Debts|PYXS (Pyxis Oncology) - Short-Term Debt Volume|Company Short-Term Debt CGEN|Company Current Liabilities IOBT|Company Short-Term Debt STRO (Sutro Biopharma, Inc.)|Company Current Liabilities minktherapeutics.com INKT|Company Current Liabilities HOWL (Werewolf Therapeutics, Inc.)|Immix Biopharma Inc. - Company Short-Term Debts|ALX Oncology (ALXO) - Company Short-Term Debt|CUE: Company Short-Term Indebtedness|Company Short-Term Debt PDSB|Short-Term Debt Sonnet BioTherapeutics Holdings|MAIA Biotechnology, Inc. - Company Current Liabilities|Short-Term Indebtedness Liminatus Pharma Inc. (LIMN)|Company Current Liabilities LAVA Therapeutics N.V.|Amount of Current Liabilities leaptx.com (LPTX)|Company Short-Term Debts Intensity Therapeutics, Inc.|Company Short-Term Loans and Borrowings Sensei Biotherapeutics Inc SNSE|TOVX (Theriva Biologics) - Company Short-Term Debts|GRTS: Short-Term Debt|Company Short-Term Debt Kineta Bio KA|NexImmune Corporation (NEXI) - Company Short-Term Loans and Borrowings|TSBX (Turnstone Biologics Corp) - Company Short-Term Debts|Company Short-Term Debts VCNX|HARP - Company Short-Term Debt